Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | CD44 | P16070 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22541598 | 1.00 | HTR2A (0.47) | HTR2ATSHRTDP1HTR2CAKR1B1 | |
| SCHEMBL14522963 | 0.90 | HTR2A (0.51) | HTR2ATSHRTDP1HTR2CAKR1B1 | |
| SCHEMBL19564578 | 0.86 | MAPK1 (0.43) | HTR2AHTR2CMAOBDRD2 | |
| SCHEMBL23855524 | 0.82 | TSHR (0.44) | HTR2ATSHRTDP1HTR2CAKR1B1 | |
| SCHEMBL29386234 | 0.82 | TSHR (0.44) | HTR2ATSHRTDP1HTR2CAKR1B1 | |
| SCHEMBL28442386 | 0.82 | TSHR (0.44) | HTR2ATSHRTDP1HTR2CAKR1B1 | |
| SCHEMBL1721598 | 0.81 | TSHR (0.42) | HTR2ATSHRTDP1AKR1B1KDM1A | |
| SCHEMBL1721595 | 0.81 | AKR1B1 (0.47) | HTR2ATSHRTDP1AKR1B1KDM1A | |
| SCHEMBL21130626 | 0.81 | HTR2A (0.36) | HTR2ATSHRTDP1AKR1B1KDM1A | |
| SCHEMBL19564579 | 0.81 | CYP2D6 (0.44) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220115-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220115-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | HTR2A 4047/4885TSHR 4456/4885TDP1 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.